Analyst Price Targets — ALVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 9:24 pm | Glen Santangelo | Barclays | $5.00 | $5.45 | TheFly | Alvotech initiated with an Underweight at Barclays |
| December 3, 2025 11:32 am | — | Morgan Stanley | $10.00 | $4.60 | TheFly | Alvotech price target lowered to $10 from $14 at Morgan Stanley |
| November 18, 2025 2:33 pm | — | UBS | $10.00 | $5.11 | TheFly | Alvotech price target lowered to $10 from $13 at UBS |
| November 4, 2025 1:17 pm | — | Northland Securities | $10.00 | $4.93 | TheFly | Alvotech price target lowered to $10 from $28 at Northland |
| November 4, 2025 9:49 am | Niall Alexander | Deutsche Bank | $8.00 | $5.03 | StreetInsider | Deutsche Bank Downgrades Alvotech SA (ALVO) to Hold |
| October 14, 2025 8:38 am | — | Morgan Stanley | $14.00 | $7.97 | TheFly | Alvotech upgraded to Overweight from Equal Weight at Morgan Stanley |
| May 24, 2024 5:26 am | Balaji Prasad | Barclays | $22.00 | $13.58 | TheFly | Alvotech price target raised to $22 from $20 at Barclays |
| May 21, 2024 2:22 pm | Balaji Prasad | Barclays | $20.00 | $13.76 | StreetInsider | Barclays Reiterates Overweight Rating on Alvotech SA (ALVO) |
| January 29, 2024 3:32 am | Balaji Prasad | Barclays | $17.00 | $15.25 | StreetInsider | Barclays Upgrades Alvotech SA (ALVO) to Overweight |
| July 1, 2022 5:05 am | Emmanuel Papadakis | Deutsche Bank | $10.00 | $8.21 | TheFly | Alvotech initiated with a Hold at Deutsche Bank |
Latest News for ALVO
Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the pledging of (i) 88,940,619 shares and (ii) 7,007,321 depository receipts on shares in Alvotech by Celtic Lux Holdings S.a. r.l. (formerly known as Alvogen Lux Holdings S.a. r.l.). The date of the transactions was June 26, 2026.
REYKJAVIK, ICELAND (July 1, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has amended its existing credit agreement with funds managed by GoldenTree Asset Management LP and other existing lenders of Alvotech to provide a term loan facility of up to $75 million in…
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 10,133,333 shares in Alvotech by Celtic Lux Holdings S.a. r.l. (formerly known as Alvogen Lux Holdings S.a. r.l.) at a price of USD 3.75 per share. The date of the transaction was June 16, 2026.
REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per…
REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has commenced an underwritten public offering of its ordinary shares (the “Offering”). In addition, Alvotech expects to grant the underwriters a…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ALVO.
Senate Trading
No Senate trades found for ALVO.
U.S. House Trading
No House trades found for ALVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.